TABLE 2.
System | Stage I | Stage II | Stage III |
---|---|---|---|
AKIN17 | SCr increase by 1.5- to 1.9-fold from baseline; SCr increase of ≥0.3 mg/dL; or urine output of <0.5 mL/kg/h >6 h | SCr increase 2.0–2.9 times baseline or urine output of <0. 5 mL/kg/h for >12 h | SCr increase 3.0 times baseline; SCr increase of ≥4.0 mg/dL with an acute increase of at least 0.5 mg/dL; or urine output of <0. 3 mL/kg/h >24 h or anuric for >12 h |
KDIGO18 | SCr increase 1.5–1.9 times baseline; or Cr increase of ≥0.3 mg/dL or urine output of <0.5 mL/kg/h for 6–12 h | SCr increase 2.0–2.9 times baseline; or urine output of <0.5 mL/kg/h for >12 h | SCr increase 3.0 times baseline; SCr increase of ≥4.0 mg/dL; initiation of renal replacement therapy; or urine output of <0.3 mL/kg/h for 24 h or anuric for >12 h |
IAC19 | SCr increase (0.3 mg/dL) or increase in SCr of ≥1.5–2.0 times from baseline | SCr increase >2.0–3.0 times from baseline | SCr increase >3.0 times from baseline; SCr of ≥4.0 mg/dL with an acute rise of 0.3 mg/dL; or initiation of renal replacement therapy |
AKIN, Acute Kidney Injury Network; IAC, International Ascites Club; KDIGO, Kidney Disease Improving Global Outcomes; SCr, serum creatinine.